SpineGuard Announces a New Partnership with Sorbonne, CNRS and Inserm to associate its DSG® Technology With Ultrasound and Serve Surgical Robots

SpineGuard | June 08, 2022

SpineGuard Announces

pineGuard an innovative company that deploys its DSG sensing technology to secure and streamline the placement of bone implants, announces the launch of a new three-year collaboration program with two labs of Sorbonne University CNRS and Inserm: the ISIR.

DSG is based on the local measurement of electrical conductivity of tissues in real time without X-ray imaging, with a sensor located at the tip of the drilling instrument. Its efficacy was proven by more than 90,000 surgeries across the globe and 19 scientific publications. SpineGuard has entered in 2017 a collaboration with ISIR for the application of DSG to surgical robots and the enhancement of their safety, accuracy, and autonomy.

SpineGuard and ISIR capitalize on first order outcomes published so far…

At the close of a first collaboration phase, SpineGuard announced sub-millimetric accuracy experimental outcomes in bone boundary detection and automatic stop of a vertebral drilling performed by a robot using the DSG technology. These impressive outcomes were presented as they were produced successively at the Hamlyn medical robotics conference in London in May 2019, receiving the first price for best scientific paper, then in plenary session at the SMISS minimally invasive spine surgery (SMISS) in Las Vegas in November 2021, and lastly during the CRAS conference in Naples in April 2022.

… and join forces with the LIB laboratory in order to add ultrasound to the project.

Encouraged by this success, the research and development teams wish to go even further in surgical robots advancement: the guidance technologies that allow the robot to position itself properly relative to the patient to find the drilling entry point rely today on X-Ray imaging, dangerous for health, in combination with space-consuming optical registration. SpineGuard has long explored the possibility to use ultrasound complementarily to DSG for this preliminary step, before the tool is penetrating bone, and was granted two families of international patents on that topic. The LIB laboratory, who features an international level expertise in the field of ultrasound imaging, answered with enthusiasm the invitation to join the project. SpineGuard, ISIR and LIB thus start a new 3-year collaboration that is expected to produce breakthrough results in the field.

We are happy to launch this partnership that will allow us to go even further in improving surgical robots in orthopedics. This new phase of the project aims at enabling robots to perform bone drilling and cutting, as well as implant placement, in a secured and more autonomous manner in the human skeleton. Our goal is to implement first-class collaboration between French Research and Industry and trigger commercial ventures in the orthopedic field via strategic agreements with industry partners.”

Stéphane Bette, co-founder and Deputy CEO of SpineGuard

Guillaume Morel, Professor at Sorbonne University and ISIR Director, and Brahim Tamadazte, Researcher at CNRS and member of ISIR, added: “We are delighted to continue the close and dynamic collaboration initiated in 2017 with SpineGuard. The entry of robotics and associated new technologies in operating room is no doubt one of the biggest medical advances of the last twenty years. Robotic approaches often allow the surgical gesture to be less invasive, more accurate, safe and intuitive in numerous surgical procedures. The first outcomes from the previous collaboration gave us more visibility on the clinical added value that a robot with original and effective sensors can bring to Orthopedic Surgery in general and Spine in particular. This new collaboration will be about ultrasonic sensors coupled with robotics. This original and promising association will allow the surgeon to define the entry point and the pedicle screw trajectory accurately and non-invasively, without relying on ionizing or costly preoperative imaging (scanner, MRI). The association of two prestigious labs of Sorbonne University (ISIR and LIB), whose competencies are highly complementary to SpineGuard’s industrial vision constitute a stimulating work environment favorable to innovation. The journey with SpineGuard goes on for three more years with a target of several technologic and scientific innovations to serve patients and care providers.”

Quentin Grimal, Professor at Sorbonne University and Manager of the team “Ultrasound and imaging for bone quality characterization” at LIB, concludes: “Using ultrasound to position a surgical tool is particularly relevant. Ultrasounds are danger free and provide real time information about interfaces, bone anatomy, even bone mechanical quality. The use of an ultrasound probe should allow to position the robotic arm in an optimal manner to place pedicle screws. In general, echography does not allow to see beyond the bone surfaces because ultrasounds are strongly reflected at the surface and strongly attenuated when propagating in bone. Low amplitude signals coming from inside bone can however be exploited through specific treatments which are a specialty of our team. Our team, pioneer in ultrasound utilization to probe bone, has introduced several approaches that offer an alternative to X-Rays for characterization of trabecular or cortical bone health. For our team, this partnership with SpineGuard and ISIR is a great fit: it will accelerate methodology and instrument developments for a broader utilization of ultrasound in orthopedic surgery. We are very happy to participate in this innovation rich project.”

About SpineGuard®

Founded in 2009 in France and the USA by Pierre Jérôme and Stéphane Bette, SpineGuard is an innovative company deploying its proprietary radiation-free real time sensing technology DSG® (Dynamic Surgical Guidance) to secure and streamline the placement of implants in the skeleton. SpineGuard designs, develops and markets medical devices that have been used in over 90,000 surgical procedures worldwide. Nineteen studies published in peer-reviewed scientific journals have demonstrated the multiple benefits DSG® offers to patients, surgeons, surgical staff and hospitals. Building on these strong fundamentals and several strategic partnerships, SpineGuard has expanded the scope of its DSG® technology in innovative applications such as the « smart » pedicle screw, the DSG Connect visualization and registration interface, dental implantology and surgical robotics. DSG® was co-invented by Maurice Bourlion, Ph.D., Ciaran Bolger, M.D., Ph.D., and Alain Vanquaethem, Biomedical Engineer. SpineGuard has engaged in multiple ESG initiatives.

About ISIR

ISIR is one of the largest French Research institutions in robotics and intelligent systems, reporting mainly to Sorbonne University, CNRS (National Center for Scientific Research) and Inserm (National institute for health and medical research). It regroups more than 50 teaching researchers and permanent researchers and approximately 80 PhD ad post-doc students. ISIR is structured around 6 research teams focused on artificial intelligence and machine learning, mobile robotics, small scale robotics, assistance robotics (physical therapy and mobility support), human-robot interaction and surgical gesture assistance. ISIR has a rich expertise in the design of innovative robotic architectures, simulation and control, clinical validation and transfer of high industrial potential results. Over the last 5 past years, 10 pre-clinical or clinical studies were conducted at ISIR. 8 patents were granted, and 2 start-up companies created.

About LIB

The Laboratory for biomedical imaging (LIB) is specialized in Fundamental and Applied Research for biomedical morphologic imaging methods, functional and molecular on small animal and human. It reports to Sorbonne University, CNRS and INSERM. It regroups 35 permanent researchers and teaching researchers, of whom half are also hospital practitioners, approximately 10 engineers and technicians and more than 30 PhD students and post-docs. LIB is structured around 6 teams whose focuses correspond to key priorities of 21st century Public Health: cancer, cardiovascular and neurologic diseases, bone quality. LIB develops new diagnostic and treatments methods exploiting various modalities: ultrasound, MRI, CT, SPECT-PET, etc. LIB has a strong commitment to technology transfer. Over the last 5 years, 6 patents were granted, 7 software were filed, and 5 startup companies launched.


Healthcare software development can facilitate health services, providing platforms and apps that help transform the healthcare industry. In today’s video we’ll talk about the benefits of medical software engineering.


Healthcare software development can facilitate health services, providing platforms and apps that help transform the healthcare industry. In today’s video we’ll talk about the benefits of medical software engineering.

Related News


Eko Launches SENSORA™, Detects Heart Disease with AI

Eko | February 24, 2023

On February 23, 2023, Eko, a digital health company employing artificial intelligence (AI) to combat heart and lung diseases, announced the launch of the SENSORATM Cardiac Disease Detection Platform. The platform features AI that detects structural murmurs, an indication of valvular heart disease, and Care Pathway Analytics software, which offers downstream visibility and metrics for the patient's journey along the healthcare system. SENSORA™ is a detection platform for cardiovascular disease that utilizes digital stethoscopes to capture and analyze heart sounds and electrical signals. This platform leverages the latest advancements in machine learning to continue expanding the platform and develop new use cases for cardiac conditions. Over 8 million Americans are diagnosed with clinically significant valvular heart disease (VHD), and one in ten older adults have a chance to develop it. Unfortunately, more than half (57%) of significant VHD cases in this population go undetected. Left untreated, VHD can cause blood clots, heart failure, and mortality. With SENSORA™'s FDA-cleared structural murmur detection, primary care physicians more than double their likelihood of detecting significant VHD. SENSORA™ Care Pathway Analytics can aid in crucial decision-making by identifying care gaps to convert them into improved operational efficiencies, ultimately improving patient and clinician satisfaction. In addition, the platform provides downstream visibility for those with identified structural murmurs by tracking clinical outcomes, patient flows, and economics throughout the care continuum. Eko currently offers five FDA 510(k) cleared digital solutions and is developing two novel machine-learning algorithms that use electrocardiogram (ECG) and heart sound data. These algorithms include "ELEFT," which detects low ejection fraction in heart failure patients, and another algorithm that detects and stratifies pulmonary hypertension. The company is dedicated to developing advanced solutions that fulfill the needs of patients and clinicians. By enabling early detection of heart and lung diseases, the company can help save lives. About Eko Eko, a digital health company based in Oakland (California), is evolving how healthcare providers diagnose and monitor heart and lung disease with its suite of innovative digital tools, patient and provider software, and AI-driven analysis. Its FDA-approved platform is employed by many healthcare professionals worldwide, enabling them to optimize detection, diagnosis, and treatment management, and ultimately provide the best care possible to their patients. It has received over $125 million in funding from Highland Capital Partners, Questa Capital, DigiTx Partners, NTTVC, Artis Ventures, Mayo Clinic, Sutter Health, and others.

Read More


Signify Health and Prospect Medical Holdings Team Up to Provide Top-notch Care

Signify Health | January 12, 2023

Signify Health, a top healthcare platform that uses advanced analytics, technology, and nationwide healthcare networks, announced a new partnership with Prospect Medical Holdings, Inc., a growing healthcare services company on January 11, 2023. The collaboration will help create and run value-based payment programs for superior care. To improve care transformation, manage risk, and provide high-quality, coordinated patient care for its traditional Medicare fee-for-service patients, Prospect's Waterbury HEALTH and Eastern Connecticut Health Network (ECHN) facilities and their affiliated provider network in Connecticut will join a Signify-enabled accountable care organization (ACO) in 2023 as part of the Medicare Shared Savings Program (MSSP). Signify Health will assist Prospect facilities in managing their MSSP ACO risk, lowering costs, and increasing quality incentives by providing data-driven, tailored population health roadmaps. Patients who seek treatment at Prospect's hospitals, which provide care to underprivileged and diverse populations across the state, will benefit from the strategic partnership. EJay Lockwood, Vice President, Connecticut Coordinated Care at Prospect Medical Holdings stated, "Every healthcare market is different to a certain extent, but we were impressed by Signify's experience that has spanned so many markets and has managed to 'stay local' while simultaneously honing their approach to delivering on the core competencies that any successful ACO needs to have." (Source: Business Wire) Tim Gronniger, Chief of Value-based Care Solutions, Signify Health, shared, "Prospect's Connecticut teams serve patients living in economically disadvantaged areas who also have been medically underserved. Through our work together, Prospect's Medicare patients will receive needed increased access to preventative and in-home services that will help improve their health outcomes, while creating a better overall experience for both patients and their care teams." (Source: Business Wire) About Signify Health At Signify Health, a renowned healthcare platform, cutting-edge analytics, technology, and national healthcare provider networks enable value-based payment options. Health plans and organizations use the company's technologies to assess risk and develop ways to enhance patient outcomes, coordination, and cost. Its platform coordinates clinical, social, and behavioral treatments. Signify Health meets customers' needs, reduces costs, and brings care closer to home.

Read More


Temple Health and Masimo Advance Patient Care Through Innovation Collaboration

Masimo | March 10, 2023

Masimo, a pioneer in technology and automation solutions for the healthcare industry, and Temple Health, a leading academic health system in Philadelphia, recently announced the formation of a strategic innovation collaboration. With a focus on advancing the forefront of telehealth and remote patient monitoring and automating high-quality care, the strategic partnership may involve using innovations such as the Radius VSMTM tetherless multimodal patient monitor, Masimo W1TM advanced health tracking watch, and various Masimo Hospital AutomationTM solutions. The collaboration aims to advance the organizations’ shared objectives of increasing care value, improving health, and transforming care delivery models. Masimo and Temple Health intend to collaborate in the following areas Raising awareness about health equity using their expertise and regional influence to improve access to quality care for Philadelphia residents. Demonstrating the future of healthcare by deploying next-generation therapies, devices, technologies, and systems to enhance patient-centered care across the care continuum, particularly in remote patient monitoring, automation, and telehealth. Joint research into healthcare technology best practices to minimize tech obsolesce in healthcare as telehealth and automation infrastructure become more sophisticated. Trial and refine the latest Masimo technologies by participating in the Temple Health ‘Collaboratory.’ Collaborative clinical research in inpatient, outpatient, and home settings, with technological innovation, cooperation and co-development. Key leaders’ engagement in clinical and technological exchanges aimed at pushing the frontiers of healthcare. Founder and CEO of Masimo, Joe Kiani, shared, “We are delighted to expand our relationship with Temple Health through this innovation collaboration and to work hand in hand to explore how Masimo’s monitoring, connectivity, and automation technologies, alongside Temple Health’s clinical expertise, can bring safe, easy-to-use, high-quality telehealth and remote patient monitoring services to their patients. We are committed to improving life, improving patient outcomes, and reducing the cost of care.” (Source – Business Wire) About Masimo Based in Irvine, California, Masimo is a global medical technology company specializing in developing and manufacturing breakthrough noninvasive patient monitoring technologies, including sensors and medical devices. For over 30 years, it has been dedicated to solving challenging problems in the medical industry. By offering clinically-proven and innovative products, and healthcare providers, the company is committed to making a measurable difference in the world by saving, prolonging, and enhancing the lives of people of every age and background. Its cutting-edge solutions offer real-time information to optimize clinical decision-making and improve patient safety.

Read More